Affitech A/S completes AT001/r84 preclinical package milestone in R&D agreement with IBC Generium
Managing Director of Affitech Martin Welschof said: “I am very pleased to see the continuing progress in the development of the drug candidate AT001/r84 leading to the payment of the first milestone in our R&D collaboration with Russian partner IBC Generium. The pre-clinical package performed under appropriate GMP or GLP procedures supports clinical trial applications in different territories.”
AT001/r84 is a novel, proprietary therapeutic antibody to vascular endothelial growth factor (VEGF) being developed by Affitech and IBC Generium as a potential alternative to bevacizumab (Avastin®) for the treatment of certain human cancers. The Russian health authorities have identified cancer therapy based on anti-VEGF antibodies as one of the top priority areas of pharma-innovation in Russia. Affitech’s AT001/r84 has the potential to satisfy patient needs in this area. The rights to develop and commercialize AT001/r84 outside Russia and the CIS remain with Affitech.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.